Roles of mTOR complexes in the kidney: implications for renal disease and transplantation (original) (raw)

• Vezina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721–726 (1975).
  Article CAS Google Scholar
• Calne, R. Y. et al. Rapamycin for immunosuppression in organ allografting. Lancet 2, 227 (1989).
  Article CAS PubMed Google Scholar
• Thomson, A. W., Turnquist, H. R. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9, 324–337 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Powell, J. D., Pollizzi, K. N., Heikamp, E. B. & Horton, M. R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39–68 (2012).
  Article CAS PubMed Google Scholar
• Shimobayashi, M. & Hall, M. N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 15, 155–162 (2014).
  Article CAS PubMed Google Scholar
• Flinn, R. J., Yan, Y., Goswami, S., Parker, P. J. & Backer, J. M. The late endosome is essential for mTORC1 signaling. Mol. Biol. Cell 21, 833–841 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, S. G. et al. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol. Cell 49, 172–185 (2013).
  Article CAS PubMed Google Scholar
• Yadav, R. B. et al. mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging. BMC Cell Biol. 14, 3 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Fournier, M. J. et al. Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation. Mol. Cell. Biol. 33, 2285–2301 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Guertin, D. A. et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11, 859–871 (2006).
  Article CAS PubMed Google Scholar
• Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 144, 757–768 (2011).
  Article CAS PubMed Google Scholar
• Xie, J. & Proud, C. G. Crosstalk between mTOR complexes. Nat. Cell Biol. 15, 1263–1265 (2013).
  Article CAS PubMed Google Scholar
• Schreiber, K. H. et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 14, 265–273 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
  Article CAS PubMed Google Scholar
• Gaubitz, C. et al. Molecular basis of the rapamycin insensitivity of target of rapamycin complex 2. Mol. Cell 58, 977–988 (2015).
  Article CAS PubMed Google Scholar
• Zeng, Z. et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109, 3509–3512 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
  Article CAS PubMed Google Scholar
• Brunn, G. J. et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256–5267 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, K. et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232–6240 (2009).
  Article CAS PubMed Google Scholar
• Bendell, J. C. et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 121, 3481–3490 (2015).
  Article CAS PubMed Google Scholar
• Pavenstadt, H., Kriz, W. & Kretzler, M. Cell biology of the glomerular podocyte. Physiol. Rev. 83, 253–307 (2003).
  Article CAS PubMed Google Scholar
• Godel, M. et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest. 121, 2197–2209 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Inoki, K. et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181–2196 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Groth, C. G. et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67, 1036–1042 (1999).
  Article CAS PubMed Google Scholar
• Schwarz, C., Bohmig, G. A., Steininger, R., Mayer, G. & Oberbauer, R. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol. Dial. Transplant. 16, 378–382 (2001).
  Article CAS PubMed Google Scholar
• da Silva, C. A. et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. Am. J. Physiol. Renal Physiol. 297, F916–F922 (2009).
  Article CAS PubMed Google Scholar
• Wu, M. S., Hung, C. C. & Chang, C. T. Renal calcium handling after rapamycin conversion in chronic allograft dysfunction. Transpl. Int. 19, 140–145 (2006).
  Article CAS PubMed Google Scholar
• Tataranni, T. et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am. J. Transplant. 11, 1656–1664 (2011).
  Article CAS PubMed Google Scholar
• Haller, M. et al. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLoS ONE 7, e39229 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kempe, D. S. et al. Rapamycin-induced phosphaturia. Nephrol. Dial. Transplant. 25, 2938–2944 (2010).
  Article CAS PubMed Google Scholar
• Gleixner, E. M. et al. V-ATPase/mTOR signaling regulates megalin-mediated apical endocytosis. Cell Rep. 8, 10–19 (2014).
  Article CAS PubMed Google Scholar
• Grahammer, F. et al. mTOR regulates endocytosis and nutrient transport in proximal tubular cells. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015111224 (2016).
• Grahammer, F. et al. mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proc. Natl Acad. Sci. USA 111, E2817–E2826 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lang, F. & Pearce, D. Regulation of the epithelial Na+ channel by the mTORC2/SGK1 pathway. Nephrol. Dial. Transplant. 31, 200–205 (2015).
  PubMed PubMed Central Google Scholar
• Lu, M. et al. mTOR complex-2 activates ENaC by phosphorylating SGK1. J. Am. Soc. Nephrol. 21, 811–818 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gleason, C. E. et al. mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity. J. Clin. Invest. 125, 117–128 (2015).
  Article PubMed Google Scholar
• Grahammer, F. et al. mTORC2 critically regulates renal potassium handling. J. Clin. Invest. 126, 1773–1782 (2016).
  Article PubMed PubMed Central Google Scholar
• Canaud, G. et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371, 303–312 (2014).
  Article CAS PubMed Google Scholar
• Jindra, P. T., Jin, Y. P., Rozengurt, E. & Reed, E. F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J. Immunol. 180, 2357–2366 (2008).
  Article CAS PubMed Google Scholar
• Jindra, P. T., Jin, Y. P., Jacamo, R., Rozengurt, E. & Reed, E. F. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem. Biophys. Res. Commun. 369, 781–787 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• de Sandes-Freitas, T. V. et al. Subclinical lesions and donor-specific antibodies in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen followed by early conversion to sirolimus. Transplantation 99, 2372–2381 (2015).
  Article CAS PubMed Google Scholar
• Liefeldt, L. et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am. J. Transplant. 12, 1192–1198 (2012).
  Article CAS PubMed Google Scholar
• Croze, L. E. et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl. Int. 27, 775–783 (2014).
  Article CAS PubMed Google Scholar
• Lepin, E. J. et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am. J. Transplant. 6, 1560–1571 (2006).
  Article CAS PubMed Google Scholar
• Jindra, P. T. et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J. Immunol. 180, 2214–2224 (2008).
  Article CAS PubMed Google Scholar
• Kim, Y. C. & Guan, K. L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25–32 (2015).
  Article PubMed PubMed Central Google Scholar
• Ganley, I. G. et al. ULK1. ATG13. FIP200 complex mediates mTOR signaling and is essential for autophagy. J. Biol. Chem. 284, 12297–12305 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hosokawa, N. et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 20, 1981–1991 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jung, C. H. et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 20, 1992–2003 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Fougeray, S. & Pallet, N. Mechanisms and biological functions of autophagy in diseased and ageing kidneys. Nat. Rev. Nephrol. 11, 34–45 (2015).
  Article CAS PubMed Google Scholar
• Hartleben, B. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120, 1084–1096 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kawakami, T. et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. J. Am. Soc. Nephrol. 26, 1040–1052 (2015).
  Article CAS PubMed Google Scholar
• Kimura, T. et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J. Am. Soc. Nephrol. 22, 902–913 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. & Longo, V. D. Regulation of longevity and stress resistance by Sch9 in yeast. Science 292, 288–290 (2001).
  Article CAS PubMed Google Scholar
• Vellai, T. et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426, 620 (2003).
  Article CAS PubMed Google Scholar
• Kapahi, P. et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885–890 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, S. C., Rabinovitch, P. S. & Kaeberlein, M. mTOR is a key modulator of ageing and age-related disease. Nature 493, 338–345 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zhuo, L. et al. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging. Mech. Ageing Dev. 130, 700–708 (2009).
  Article CAS PubMed Google Scholar
• Zhang, S. et al. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mech. Ageing Dev. 133, 387–400 (2012).
  Article CAS PubMed Google Scholar
• Weichhart, T., Hengstschlager, M. & Linke, M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15, 599–614 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Fantus, D. & Thomson, A. W. Evolving perspectives of mTOR complexes in immunity and transplantation. Am. J. Transplant. 15, 891–902 (2015).
  Article CAS PubMed Google Scholar
• Lo, Y. C., Lee, C. F. & Powell, J. D. Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection. Curr. Opin. Organ. Transplant 19, 363–371 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Turner, J. E., Paust, H. J., Steinmetz, O. M. & Panzer, U. The Th17 immune response in renal inflammation. Kidney Int. 77, 1070–1075 (2010).
  Article CAS PubMed Google Scholar
• Rogers, N. M., Ferenbach, D. A., Isenberg, J. S., Thomson, A. W. & Hughes, J. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat. Rev. Nephrol. 10, 625–643 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat. Med. 21, 688–697 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Batal, I. et al. Dendritic cells in kidney transplant biopsy samples are associated with T cell infiltration and poor allograft survival. J. Am. Soc. Nephrol. 26, 3102–3113 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Turnquist, H. R. et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178, 7018–7031 (2007).
  Article CAS PubMed Google Scholar
• Hackstein, H. et al. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101, 4457–4463 (2003).
  Article CAS PubMed Google Scholar
• Turnquist, H. R. et al. mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 115, 4758–4769 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Amiel, E. et al. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J. Immunol. 189, 2151–2158 (2012).
  Article CAS PubMed Google Scholar
• Brown, J., Wang, H., Suttles, J., Graves, D. T. & Martin, M. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J. Biol. Chem. 286, 44295–44305 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Raich-Regue, D. et al. mTORC2 deficiency in myeloid dendritic cells enhances their allogeneic Th1 and Th17 stimulatory ability after TLR4 ligation in vitro and in vivo. J. Immunol. 194, 4767–4776 (2015).
  Article CAS PubMed Google Scholar
• Raich-Regue, D. et al. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8C effector T cell responses. Oncoimmunology http://dx.doi.org/10.1080/2162402X.2016.1146841 (2016).
• Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325–338 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, K. et al. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J. Exp. Med. 209, 713–728 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Tian, L., Lu, L., Yuan, Z., Lamb, J. R. & Tam, P. K. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 77, 183–189 (2004).
  Article CAS PubMed Google Scholar
• Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565–574 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743–4748 (2005).
  Article CAS PubMed Google Scholar
• Zeng, H. et al. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499, 485–490 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ray, J. P. et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity 43, 690–702 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Matz, M. et al. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. Transpl. Int. 25, 1106–1116 (2012).
  Article CAS PubMed Google Scholar
• Benhamron, S. & Tirosh, B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. Eur. J. Immunol. 41, 2390–2396 (2011).
  Article CAS PubMed Google Scholar
• Lee, K. et al. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 122, 2369–2379 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Keating, R. et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat. Immunol. 14, 1266–1276 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Limon, J. J. et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc. Natl Acad. Sci. USA 111, E5076–E5085 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Jin, Y. P., Valenzuela, N. M., Ziegler, M. E., Rozengurt, E. & Reed, E. F. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am. J. Transplant. 14, 806–819 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Marcais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15, 749–757 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Shin, B. H. et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation 97, 294–300 (2014).
  Article CAS PubMed Google Scholar
• Prevot, N. et al. Mammalian target of rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger. J. Immunol. 194, 223–230 (2015).
  Article CAS PubMed Google Scholar
• Ochiai, T. et al. Effects of rapamycin in experimental organ allografting. Transplantation 56, 15–19 (1993).
  Article CAS PubMed Google Scholar
• Stepkowski, S. M., Chen, H., Daloze, P. & Kahan, B. D. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 51, 22–26 (1991).
  Article CAS PubMed Google Scholar
• Poston, R. S. et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100, 67–74 (1999).
  Article CAS PubMed Google Scholar
• Ikonen, T. S. et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70, 969–975 (2000).
  Article CAS PubMed Google Scholar
• Nakamura, T., Nakao, T., Yoshimura, N. & Ashihara, E. Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells. Am. J. Transplant. 15, 2364–2377 (2015).
  Article CAS PubMed Google Scholar
• Page, A. et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am. J. Transplant. 12, 115–125 (2012).
  Article CAS PubMed Google Scholar
• Pan, H. et al. The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells. Inflammation 37, 756–765 (2014).
  Article CAS PubMed Google Scholar
• Rosborough, B. R. et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am. J. Transplant. 14, 2173–2180 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, L. et al. Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways. Transplantation 96, 782–790 (2013).
  Article PubMed Google Scholar
• Murgia, M. G., Jordan, S. & Kahan, B. D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49, 209–216 (1996).
  Article CAS PubMed Google Scholar
• MacDonald, A. S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71, 271–280 (2001).
  Article CAS PubMed Google Scholar
• Kahan, B. D., Julian, B. A., Pescovitz, M. D., Vanrenterghem, Y. & Neylan, J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68, 1526–1532 (1999).
  Article CAS PubMed Google Scholar
• Kahan, B. D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune, US Study Group. Lancet 356, 194–202 (2000).
  Article CAS PubMed Google Scholar
• Kreis, H. et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69, 1252–1260 (2000).
  Article CAS PubMed Google Scholar
• Kreis, H. et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J. Am. Soc. Nephrol. 15, 809–817 (2004).
  Article CAS PubMed Google Scholar
• Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562–2575 (2007).
  Article CAS PubMed Google Scholar
• Flechner, S. M. et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 11, 1633–1644 (2011).
  Article CAS PubMed Google Scholar
• Webster, A. C., Lee, V. W., Chapman, J. R. & Craig, J. C. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst. Rev., CD004290 (2006).
• Lim, W. H. et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am. J. Transplant. 14, 2106–2119 (2014).
  Article CAS PubMed Google Scholar
• Su, L. et al. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis. Int. Urol. Nephrol. 46, 2035–2044 (2014).
  Article CAS PubMed Google Scholar
• Murakami, N., Riella, L. V. & Funakoshi, T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am. J. Transplant. 14, 2317–2327 (2014).
  Article CAS PubMed Google Scholar
• Mandelbrot, D. A. et al. Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus. Am. J. Transplant. 15, 3174–3184 (2015).
  Article CAS PubMed Google Scholar
• Lewkowicz, N. et al. Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis. J. Oral Pathol. Med. 37, 454–461 (2008).
  Article PubMed Google Scholar
• Sabbatini, M. et al. Oscillatory mTOR inhibition and Treg increase in kidney transplantation. Clin. Exp. Immunol. 182, 230–240 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Morelon, E. et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72, 787–790 (2001).
  Article CAS PubMed Google Scholar
• Joannides, R. et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am. J. Transplant. 11, 2414–2422 (2011).
  Article CAS PubMed Google Scholar
• Thierry, A. et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am. J. Transplant. 11, 2153–2161 (2011).
  Article CAS PubMed Google Scholar
• Heilman, R. L. et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 92, 767–773 (2011).
  Article CAS PubMed Google Scholar
• Glotz, D. et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 89, 1511–1517 (2010).
  Article CAS PubMed Google Scholar
• Li, H. & Pauza, C. D. Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro. Cancer Immunol. Immunother. 60, 361–370 (2011).
  Article CAS PubMed Google Scholar
• Clippinger, A. J., Maguire, T. G. & Alwine, J. C. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J. Virol. 85, 3930–3939 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hirsch, H. H., Yakhontova, K., Lu, M. & Manzetti, J. BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am. J. Transplant. 16, 821–832 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrer, I. R. et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J. Immunol. 185, 2004–2008 (2010).
  Article CAS PubMed Google Scholar
• Nashan, B. et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93, 1075–1085 (2012).
  Article CAS PubMed Google Scholar
• Tedesco-Silva, H. et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am. J. Transplant. 15, 2655–2664 (2015).
  Article CAS PubMed Google Scholar
• Polanco, N. et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant Proc. 47, 57–61 (2015).
  Article CAS PubMed Google Scholar
• Knoll, G. A. et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349, g6679 (2014).
  Article PubMed PubMed Central Google Scholar
• Diekmann, F. et al. Treatment with sirolimus is associated with less weight gain after kidney transplantation. Transplantation 96, 480–486 (2013).
  Article CAS PubMed Google Scholar
• Halleck, F. et al. An evaluation of sirolimus in renal transplantation. Expert Opin. Drug Metab. Toxicol. 8, 1337–1356 (2012).
  Article CAS PubMed Google Scholar
• Susantitaphong, P. et al. World incidence of AKI: a meta-analysis. Clin. J. Am. Soc. Nephrol. 8, 1482–1493 (2013).
  Article PubMed PubMed Central Google Scholar
• Rimes-Stigare, C. et al. Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study. Crit. Care 19, 221 (2015).
  Article PubMed PubMed Central Google Scholar
• Himmelfarb, J. & Ikizler, T. A. Acute kidney injury: changing lexicography, definitions, and epidemiology. Kidney Int. 71, 971–976 (2007).
  Article CAS PubMed Google Scholar
• Smith, K. D. et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J. Am. Soc. Nephrol. 14, 1037–1045 (2003).
  Article CAS PubMed Google Scholar
• McTaggart, R. A. et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am. J. Transplant. 3, 416–423 (2003).
  Article CAS PubMed Google Scholar
• Loverre, A. et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J. Am. Soc. Nephrol. 15, 2675–2686 (2004).
  Article CAS PubMed Google Scholar
• Goncalves, G. M. et al. The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury. Transplant Proc. 39, 417–420 (2007).
  Article CAS PubMed Google Scholar
• Fuller, T. F. et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76, 1594–1599 (2003).
  Article CAS PubMed Google Scholar
• Inman, S. R. et al. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury. Urology 62, 750–754 (2003).
  Article PubMed Google Scholar
• Cicora, F. et al. Sirolimus in kidney transplant donors and clinical and histologic improvement in recipients: rat model. Transplant. Proc. 42, 365–370 (2010).
  Article CAS PubMed Google Scholar
• Lieberthal, W. et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am. J. Physiol. Renal Physiol. 281, F693–F706 (2001).
  Article CAS PubMed Google Scholar
• Lui, S. L. et al. Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl. Int. 19, 834–839 (2006).
  Article CAS PubMed Google Scholar
• Yang, B. et al. Inflammation and caspase activation in long-term renal ischemia/reperfusion injury and immunosuppression in rats. Kidney Int. 68, 2050–2067 (2005).
  Article CAS PubMed Google Scholar
• Khan, S. et al. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell Cardiol. 41, 256–264 (2006).
  Article CAS PubMed Google Scholar
• Cicora, F. et al. Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model. Clin. Exp. Immunol. 167, 169–177 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Viklicky, O. et al. Effect of sirolimus on renal ischaemia/reperfusion injury in normotensive and hypertensive rats. Transpl. Int. 17, 432–441 (2004).
  CAS PubMed Google Scholar
• Goncalves, G. M. et al. The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury. Kidney Int. 70, 1742–1749 (2006).
  Article CAS PubMed Google Scholar
• Nakagawa, S., Nishihara, K., Inui, K. & Masuda, S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur. J. Pharmacol. 696, 143–154 (2012).
  Article CAS PubMed Google Scholar
• Kezic, A., Thaiss, F., Becker, J. U., Tsui, T. Y. & Bajcetic, M. Effects of everolimus on oxidative stress in kidney model of ischemia/reperfusion injury. Am. J. Nephrol. 37, 291–301 (2013).
  Article CAS PubMed Google Scholar
• Izzedine, H. et al. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann. Oncol. 24, 2421–2425 (2013).
  Article CAS PubMed Google Scholar
• Rai, P. et al. mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN. Am. J. Physiol. Renal Physiol. 305, F343–354 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Axelsson, J., Rippe, A. & Rippe, B. Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. Am. J. Physiol. Renal Physiol. 298, F1306–F1312 (2010).
  Article CAS PubMed Google Scholar
• Kuwabara, A., Satoh, M., Tomita, N., Sasaki, T. & Kashihara, N. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia 53, 2056–2065 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• McCarthy, E. T. et al. TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J. Am. Soc. Nephrol. 9, 433–438 (1998).
  CAS PubMed Google Scholar
• Axelsson, J., Rippe, A., Oberg, C. M. & Rippe, B. Rapid, dynamic changes in glomerular permeability to macromolecules during systemic angiotensin II (ANG II) infusion in rats. Am. J. Physiol. Renal Physiol. 303, F790–F799 (2012).
  Article CAS PubMed Google Scholar
• Axelsson, J. Rippe, A. & Rippe, B. mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside. Am. J. Physiol. Renal Physiol. 308, F1056–F1064 (2015).
  Article CAS PubMed Google Scholar
• Stylianou, K. et al. Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice. Nephrol. Dial. Transplant. 27, 3141–3148 (2012).
  Article CAS PubMed Google Scholar
• DiJoseph, J. F., Sharma, R. N. & Chang, J. Y. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 53, 507–513 (1992).
  Article CAS PubMed Google Scholar
• Di Joseph, J. F. & Sehgal, S. N. Functional and histopathologic effects of rapamycin on mouse kidney. Immunopharmacol. Immunotoxicol. 15, 45–56 (1993).
  Article CAS PubMed Google Scholar
• Andoh, T. F., Burdmann, E. A., Fransechini, N., Houghton, D. C. & Bennett, W. M. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 50, 1110–1117 (1996).
  Article CAS PubMed Google Scholar
• DiJoseph, J. F., Mihatsch, M. J. & Sehgal, S. N. Renal effects of rapamycin in the spontaneously hypertensive rat. Transpl. Int. 7, 83–88 (1994).
  Article CAS PubMed Google Scholar
• Grahammer, F., Wanner, N. & Huber, T. B. mTOR controls kidney epithelia in health and disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i9–i18 (2014).
  Article PubMed Google Scholar
• Mao, J. et al. Mammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation. Am. J. Physiol. Renal Physiol. 307, F1023–F1032 (2014).
  Article CAS PubMed Google Scholar
• Jeruschke, S. et al. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PLoS ONE 8, e55980 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Letavernier, E. et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol. Dial. Transplant. 24, 630–638 (2009).
  Article CAS PubMed Google Scholar
• Muller-Krebs, S. et al. Cellular effects of everolimus and sirolimus on podocytes. PLoS ONE 8, e80340 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Vollenbroker, B. et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am. J. Physiol. Renal Physiol. 296, F418–F426 (2009).
  Article CAS PubMed Google Scholar
• Canaud, G. et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat. Med. 19, 1288–1296 (2013).
  Article CAS PubMed Google Scholar
• Narres, M. et al. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: A systematic review. PLoS ONE 11, e0147329 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Ibrahim, H. N. & Hostetter, T. H. Diabetic nephropathy. J. Am. Soc. Nephrol. 8, 487–493 (1997).
  CAS PubMed Google Scholar
• Mori, H. et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Commun. 384, 471–475 (2009).
  Article CAS PubMed Google Scholar
• Chen, J. K., Chen, J., Thomas, G., Kozma, S. C. & Harris, R. C. S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am. J. Physiol. Renal Physiol. 297, F585–F593 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sakaguchi, M. et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem. Biophys. Res. Commun. 340, 296–301 (2006).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 27, 495–502 (2007).
  Article CAS PubMed Google Scholar
• Lloberas, N. et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17, 1395–1404 (2006).
  Article CAS PubMed Google Scholar
• Eid, A. A. et al. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 62, 2935–2947 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Stylianou, K. et al. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol. Dial. Transplant. 26, 498–508 (2011).
  Article CAS PubMed Google Scholar
• Lui, S. L. et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 23, 2768–2776 (2008).
  Article CAS PubMed Google Scholar
• Lui, S. L. et al. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 17, 305–313 (2008).
  Article CAS PubMed Google Scholar
• Ramos-Barron, A. et al. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 16, 775–781 (2007).
  Article CAS PubMed Google Scholar
• Warner, L. M., Adams, L. M. & Sehgal, S. N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 37, 289–297 (1994).
  Article CAS PubMed Google Scholar
• Yap, D. Y., Ma, M. K., Tang, C. S. & Chan, T. M. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrol. (Carlton) 17, 676–680 (2012).
  Article CAS Google Scholar
• Fernandez, D., Bonilla, E., Mirza, N., Niland, B. & Perl, A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983–2988 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Greka, A. & Mundel, P. Cell biology and pathology of podocytes. Annu. Rev. Physiol. 74, 299–323 (2012).
  Article CAS PubMed Google Scholar
• Ito, N. et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest. 91, 1584–1595 (2011).
  Article CAS PubMed Google Scholar
• Lui, S. L. et al. Rapamycin attenuates the severity of murine adriamycin nephropathy. Am. J. Nephrol. 29, 342–352 (2009).
  Article CAS PubMed Google Scholar
• Ramadan, R. et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol. Dial. Transplant. 27, 2231–2241 (2012).
  Article CAS PubMed Google Scholar
• Keller, K. et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol. Dial. Transplant. 21, 2724–2735 (2006).
  Article CAS PubMed Google Scholar
• Bagchus, W. M., Hoedemaeker, P. J., Rozing, J. & Bakker, W. W. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest. 55, 680–687 (1986).
  CAS PubMed Google Scholar
• Wittmann, S. et al. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp. Nephrol. 108, e45–e56 (2008).
  Article CAS PubMed Google Scholar
• Daniel, C., Ziswiler, R., Frey, B., Pfister, M. & Marti, H. P. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp. Nephrol. 8, 52–62 (2000).
  Article CAS PubMed Google Scholar
• Daniel, C. et al. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am. J. Transplant. 5, 2849–2861 (2005).
  Article CAS PubMed Google Scholar
• Vogelbacher, R., Wittmann, S., Braun, A., Daniel, C. & Hugo, C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84, 1492–1499 (2007).
  Article CAS PubMed Google Scholar
• Tian, J., Wang, Y., Liu, X., Zhou, X. & Li, R. Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms. Exp. Biol. Med. (Maywood) 240, 936–945 (2015).
  Article CAS Google Scholar
• Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G. & Hunter, J. L. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc. Soc. Exp. Biol. Med. 100, 660–664 (1959).
  Article CAS PubMed Google Scholar
• Farquhar, M. G., Saito, A., Kerjaschki, D. & Orlando, R. A. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J. Am. Soc. Nephrol. 6, 35–47 (1995).
  CAS PubMed Google Scholar
• Naumovic, R. et al. Effects of rapamycin on active Heymann nephritis. Am. J. Nephrol. 27, 379–389 (2007).
  Article CAS PubMed Google Scholar
• Stratakis, S. et al. Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy. Clin. Dev. Immunol. 941, 93 (2013).
  Google Scholar
• Kurayama, R. et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest. 91, 992–1006 (2011).
  Article CAS PubMed Google Scholar
• Hochegger, K. et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J. Am. Soc. Nephrol. 19, 1520–1529 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kirsch, A. H. et al. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am. J. Physiol. Renal Physiol. 303, F569–F575 (2012).
  Article CAS PubMed Google Scholar
• Cruzado, J. M. et al. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol. Dial. Transplant. 26, 3596–3602 (2011).
  Article CAS PubMed Google Scholar
• Tumlin, J. A. et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 1, 109–116 (2006).
  Article CAS PubMed Google Scholar
• Cho, M. E., Hurley, J. K. & Kopp, J. B. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am. J. Kidney Dis. 49, 310–317 (2007).
  Article CAS PubMed Google Scholar
• Letavernier, E. et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin. J. Am. Soc. Nephrol. 2, 326–333 (2007).
  Article CAS PubMed Google Scholar
• Patel, P., Pal, S., Ashley, C., Sweny, P. & Burns, A. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol. Dial. Transplant. 20, 985–987 (2005).
  Article PubMed Google Scholar
• Ong, A. C., Devuyst, O., Knebelmann, B. & Walz, G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993–2002 (2015).
  Article PubMed Google Scholar
• Grantham, J. J. Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477–1485 (2008).
  Article CAS PubMed Google Scholar
• Hildebrandt, F., Benzing, T. & Katsanis, N. Ciliopathies. N. Engl. J. Med. 364, 1533–1543 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Tao, Y., Kim, J., Schrier, R. W. & Edelstein, C. L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16, 46–51 (2005).
  Article CAS PubMed Google Scholar
• Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466–5471 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Renken, C., Fischer, D. C., Kundt, G., Gretz, N. & Haffner, D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol. Dial. Transplant. 26, 92–100 (2011).
  Article CAS PubMed Google Scholar
• Belibi, F., Ravichandran, K., Zafar, I., He, Z. & Edelstein, C. L. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am. J. Physiol. Renal Physiol. 300, F236–F244 (2011).
  Article CAS PubMed Google Scholar
• Distefano, G. et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol. Cell. Biol. 29, 2359–2371 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Boehlke, C. et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 12, 1115–1122 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Boletta, A. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathog. 2, 6 (2009).
  Google Scholar
• Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl Acad. Sci. USA 108, 2462–2467 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Huber, T. B., Walz, G. & Kuehn, E. W. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int. 79, 502–511 (2011).
  Article CAS PubMed Google Scholar
• Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820–829 (2010).
  Article CAS PubMed Google Scholar
• Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830–840 (2010).
  Article CAS PubMed Google Scholar
• Grantham, J. J., Bennett, W. M. & Perrone, R. D. mTOR inhibitors and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 364, 286–287 (2011).
  Article CAS PubMed Google Scholar
• Levey, A. S. & Stevens, L. A. mTOR inhibitors and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 364, 287 (2011).
  CAS PubMed Google Scholar
• Novalic, Z. et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J. Am. Soc. Nephrol. 23, 842–853 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Perico, N. et al. Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol. 21, 1031–1040 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Riegersperger, M., Herkner, H. & Sunder-Plassmann, G. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial. Trials 16, 182 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Braun, W. E., Schold, J. D., Stephany, B. R., Spirko, R. A. & Herts, B. R. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin. J. Am. Soc. Nephrol. 9, 881–888 (2014).
  Article PubMed PubMed Central Google Scholar
• Ravichandran, K. et al. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum. Mol. Genet. 23, 4919–4931 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, S., Bicknell, G. R., Whiting, P. H. & Nicholson, M. L. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc. 33, 556–558 (2001).
  Article CAS PubMed Google Scholar
• Jolicoeur, E. M. et al. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 75, 54–59 (2003).
  Article CAS PubMed Google Scholar
• Rangan, G. K. & Coombes, J. D. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 22, 2175–2182 (2007).
  Article CAS PubMed Google Scholar
• Wu, M. J. et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 69, 2029–2036 (2006).
  Article CAS PubMed Google Scholar
• Bonegio, R. G. et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J. Am. Soc. Nephrol. 16, 2063–2072 (2005).
  Article CAS PubMed Google Scholar
• Kramer, S. et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am. J. Physiol. Renal Physiol. 294, F440–F449 (2008).
  Article CAS PubMed Google Scholar
• Li, J. et al. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis. Kidney Int. 88, 515–527 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Grahammer, F. Halting renal fibrosis: an unexpected role for mTORC2 signaling. Kidney Int. 88, 437–439 (2015).
  Article CAS PubMed Google Scholar
• Chen, G. et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS ONE 7, e33626 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rahimi, R. A. et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-β. Cancer Res. 69, 84–93 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, L. et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J. Am. Soc. Nephrol. 24, 1114–1126 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Dey, N., Ghosh-Choudhury, N., Kasinath, B. S. & Choudhury, G. G. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS ONE 7, e42316 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Koch, M., Mengel, M., Poehnert, D. & Nashan, B. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 83, 498–505 (2007).
  Article CAS PubMed Google Scholar
• Viklicky, O. et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 69, 497–502 (2000).
  Article CAS PubMed Google Scholar
• Lutz, J., Zou, H., Liu, S., Antus, B. & Heemann, U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76, 508–515 (2003).
  Article CAS PubMed Google Scholar
• Luo, L., Sun, Z. & Luo, G. Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy. J. Surg. Res. 179, e255–263 (2013).
  Article CAS PubMed Google Scholar
• Liu, Q. et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 73, 2574–2586 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Palin, N. K., Savikko, J. & Koskinen, P. K. Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury. Transpl. Int. 26, 195–205 (2013).
  Article CAS PubMed Google Scholar
• Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J. Cell. Physiol. 227, 493–507 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pontrelli, P. et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85, 125–134 (2008).
  Article CAS PubMed Google Scholar
• Diekmann, F. et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J. Am. Soc. Nephrol. 18, 2653–2660 (2007).
  Article CAS PubMed Google Scholar
• Kurdian, M. et al. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS ONE 7, e32516 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Budde, K. & Gaedeke, J. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am. J. Kidney Dis. 59, 276–283 (2012).
  Article CAS PubMed Google Scholar
• Hallett, L., Foster, T., Liu, Z., Blieden, M. & Valentim, J. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr. Med. Res. Opin. 27, 1571–1583 (2011).
  Article PubMed Google Scholar
• Osborne, J. P., Fryer, A. & Webb, D. Epidemiology of tuberous sclerosis. Ann. NY Acad. Sci. 615, 125–127 (1991).
  Article CAS PubMed Google Scholar
• Curatolo, P. et al. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: Evidence-based and expert opinions. Drugs 76, 551–565 (2016).
  Article CAS PubMed Google Scholar
• Kotulska, K., Borkowska, J. & Jozwiak, S. Possible prevention of tuberous sclerosis complex lesions. Pediatrics 132, e239–242 (2013).
  Article PubMed Google Scholar
• Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Dabora, S. L. et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 6, e23379 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Cabrera-Lopez, C. et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J. Rare Dis. 7, 87 (2012).
  Article PubMed PubMed Central Google Scholar
• Staehler, M. et al. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. Int. Urol. Nephrol. 44, 1657–1661 (2012).
  Article PubMed Google Scholar
• Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817–824 (2013).
  Article CAS PubMed Google Scholar
• Bissler, J. J. et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol. Dial. Transplant. 31, 111–119 (2016).
  Article CAS PubMed Google Scholar
• Pal, S. K. & Quinn, D. I. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat. Rev. 39, 709–719 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hutson, T. E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 760–767 (2014).
  Article CAS PubMed Google Scholar
• Flaherty, K. T. et al. BEST: a randomized Phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804). J. Clin. Oncol. 33, 2384–2391 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Wander, S. A., Hennessy, B. T. & Slingerland, J. M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 121, 1231–1241 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, B. et al. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. Cancer Lett. 357, 468–475 (2015).
  Article CAS PubMed Google Scholar
• Powles, T. et al. A randomised Phase 2 Study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur. Urol. 69, 450–456 (2015).
  Article CAS PubMed Google Scholar
• Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128–135 (2002).
  Article CAS PubMed Google Scholar
• Ghosh, A. P. et al. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget 6, 17895–17910 (2015).
  Article PubMed PubMed Central Google Scholar
• Nichols, L. A., Adang, L. A. & Kedes, D. H. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS ONE 6, e14535 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Roy, S. & Arav-Boger, R. New cell-signaling pathways for controlling cytomegalovirus replication. Am. J. Transplant. 14, 1249–1258 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Stallone, G. et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352, 1317–1323 (2005).
  Article CAS PubMed Google Scholar
• Geissler, E. K. Post-transplantation malignancies: here today, gone tomorrow? Nat. Rev. Clin. Oncol. 12, 705–717 (2015).
  Article CAS PubMed Google Scholar
• Geissler, E. K. et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label Phase 3 trial. Transplantation 100, 116–125 (2016).
  Article CAS PubMed Google Scholar
• Halleck, F. & Budde, K. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat. Rev. Nephrol. 8, 687–689 (2012).
  Article CAS PubMed Google Scholar
• Hosseini-Moghaddam, S. M., Soleimanirahbar, A., Mazzulli, T., Rotstein, C. & Husain, S. Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl. Infect. Dis. 14, 338–345 (2012).
  Article CAS PubMed Google Scholar
• Campbell, S. B., Walker, R., Tai, S. S., Jiang, Q. & Russ, G. R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am. J. Transplant. 12, 1146–1156 (2012).
  Article CAS PubMed Google Scholar
• Euvrard, S. et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N. Engl. J. Med. 367, 329–339 (2012).
  Article CAS PubMed Google Scholar
• Di Paolo, S., Teutonico, A., Ranieri, E., Gesualdo, L. & Schena, P. F. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am. J. Kidney Dis. 49, 462–470 (2007).
  Article CAS PubMed Google Scholar
• Yanik, E. L. et al. Sirolimus use and cancer incidence among US kidney transplant recipients. Am. J. Transplant. 15, 129–136 (2015).
  Article CAS PubMed Google Scholar
• Raich-Regue, D., Rosborough, B. R., Turnquist, H. R. & Thomson, A. W. Myeloid dendritic cell-specific mTORC2 deficiency enhances alloreactive Th1 and Th17 cell responses and skin graft rejection. Am J. Transplant 14, 18[Abstract 584] (2014).
  Google Scholar
• Weichhart, T. et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29, 565–577 (2008).
  Article CAS PubMed Google Scholar
• Haidinger, M. et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J. Immunol. 185, 3919–3931 (2010).
  Article CAS PubMed Google Scholar
• Cao, W. et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI3K-mTOR-p70S6K pathway. Nat. Immunol. 9, 1157–1164 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Boor, P. P., Metselaar, H. J., Mancham, S., van der Laan, L. J. & Kwekkeboom, J. Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions. Clin. Exp. Immunol. 174, 389–401 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, K. et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743–753 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Berezhnoy, A., Castro, I., Levay, A., Malek, T. R. & Gilboa, E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J. Clin. Invest. 124, 188–197 (2014).
  Article CAS PubMed Google Scholar
• Liacini, A., Seamone, M. E., Muruve, D. A. & Tibbles, L. A. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 90, 1450–1457 (2010).
  Article CAS PubMed Google Scholar
• McInturff, A. M. et al. Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1α. Blood 120, 3118–3125 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Vitiello, D., Neagoe, P. E., Sirois, M. G. & White, M. Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. Cell. Mol. Immunol. 12, 40–52 (2015).
  Article CAS PubMed Google Scholar
• He, Y. et al. Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton. Mol. Biol. Cell 24, 3369–3380 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, L., Gritz, D. & Parent, C. A. PKCβII acts downstream of chemoattractant receptors and mTORC2 to regulate cAMP production and myosin II activity in neutrophils. Mol. Biol. Cell 25, 1446–1457 (2014).
  Article PubMed PubMed Central Google Scholar
• Zhang, L. et al. Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. J. Immunol. 193, 1759–1765 (2014).
  Article CAS PubMed Google Scholar
• Wei, J., Yang, K. & Chi, H. Cutting edge: discrete functions of mTOR signaling in invariant NKT cell development and NKT17 fate decision. J. Immunol. 193, 4297–4301 (2014).
  Article CAS PubMed Google Scholar
• Zhang, S. et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117, 1228–1238 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, Y. et al. Rictor is required for early B cell development in bone marrow. PLoS ONE 9, e103970 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lazorchak, A. S. et al. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol. Cell 39, 433–443 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C. et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J. Clin. Invest. 123, 1677–1693 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C. et al. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. J. Exp. Med. 211, 395–404 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, R. W. et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72, 777–786 (2001).
  Article CAS PubMed Google Scholar
• Gonwa, T. A., Hricik, D. E., Brinker, K., Grinyo, J. M. & Schena, F. P. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74, 1560–1567 (2002).
  Article CAS PubMed Google Scholar
• Oberbauer, R. et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76, 364–370 (2003).
  Article CAS PubMed Google Scholar
• Oberbauer, R. et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl. Int. 18, 22–28 (2005).
  Article CAS PubMed Google Scholar
• Larson, T. S. et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant. 6, 514–522 (2006).
  Article CAS PubMed Google Scholar
• Buchler, M. et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am. J. Transplant. 7, 2522–2531 (2007).
  Article CAS PubMed Google Scholar
• Lebranchu, Y. et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study. Am. J. Transplant. 12, 1801–1810 (2012).
  Article CAS PubMed Google Scholar
• Gatault, P. et al. Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation. Transpl. Int. 29, 41–50 (2016).
  Article CAS PubMed Google Scholar
• Ekberg, H. et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am. J. Transplant. 9, 1876–1885 (2009).
  Article CAS PubMed Google Scholar
• Lebranchu, Y. et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am. J. Transplant. 9, 1115–1123 (2009).
  Article CAS PubMed Google Scholar
• Lebranchu, Y. et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am. J. Transplant. 11, 1665–1675 (2011).
  Article CAS PubMed Google Scholar
• Guba, M. et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 90, 175–183 (2010).
  Article CAS PubMed Google Scholar
• Guba, M. et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation. Transpl. Int. 25, 416–423 (2012).
  Article CAS PubMed Google Scholar
• Budde, K. et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377, 837–847 (2011).
  Article CAS PubMed Google Scholar
• Budde, K. et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am. J. Transplant 15, 119–128 (2015).
  Article CAS PubMed Google Scholar
• Holdaas, H. et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 92, 410–418 (2011).
  Article CAS PubMed Google Scholar
• Weir, M. R. et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 79, 897–907 (2011).
  Article CAS PubMed Google Scholar
• Weir, M. R. et al. Long-term follow-up of kidney transplant recipients in the spare-the-nephron-trial. Transplantation http://dx.doi.org/10.1097/TP.0000000000001098 (2016).
• Mjornstedt, L. et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am. J. Transplant 12, 2744–2753 (2012).
  Article CAS PubMed Google Scholar
• Mjornstedt, L. et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transpl. Int. 28, 42–51 (2015).
  Article CAS PubMed Google Scholar
• Budde, K. et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin. Nephrol. 83, 11–21 (2015).
  Article CAS PubMed Google Scholar
• Reitamo, S. et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. J. Dermatol. 145, 438–445 (2001).
  Article CAS PubMed Google Scholar
• Senior, P. A., Paty, B. W., Cockfield, S. M., Ryan, E. A. & Shapiro, A. M. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am. J. Transplant. 5, 2318–2323 (2005).
  Article PubMed Google Scholar
• Constantinescu, A. R., Liang, M. & Laskow, D. A. Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation. Am. J. Kidney Dis. 40, 407–410 (2002).
  Article PubMed Google Scholar
• Koening, C. L., Hernandez-Rodriguez, J., Molloy, E. S., Clark, T. M. & Hoffman, G. S. Limited utility of rapamycin in severe, refractory Wegener's granulomatosis. J. Rheumatol 36, 116–119 (2009).
  Article CAS PubMed Google Scholar
• Fervenza, F. C. et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol. Dial. Transplant. 19, 1288–1292 (2004).
  Article CAS PubMed Google Scholar
• Kim, H. J. & Edelstein, C. L. Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside. Kidney Res. Clin. Pract. 31, 132–138 (2012).
  Article PubMed PubMed Central Google Scholar
• Lieberthal, W., Fuhro, R., Andry, C., Patel, V. & Levine, J. S. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 82, 17–22 (2006).
  Article CAS PubMed Google Scholar
• Lee, L. et al. Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213–227 (2005).
  Article CAS PubMed Google Scholar
• Zhang, H. et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS ONE 8, e54918 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Chiarini, F., Evangelisti, C., McCubrey, J. A. & Martelli, A. M. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol. Sci. 36, 124–135 (2015).
  Article CAS PubMed Google Scholar
• Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
  Article CAS PubMed Google Scholar
• Mita, M. M. et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26, 361–367 (2008).
  Article CAS PubMed Google Scholar
• Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909–918 (2004).
  Article CAS PubMed Google Scholar